Invenomic Capital Management’s Lexaria Bioscience LEXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $436K | Sell |
501,468
-48,479
| -9% | -$42.2K | 0.02% | 146 |
|
|
2025
Q1 | $940K | Buy |
549,947
+139,216
| +34% | +$238K | 0.05% | 162 |
|
|
2024
Q4 | $863K | Sell |
410,731
-65,042
| -14% | -$137K | 0.04% | 151 |
|
|
2024
Q3 | $1.45M | Sell |
475,773
-37,800
| -7% | -$115K | 0.08% | 139 |
|
|
2024
Q2 | $1.43M | Buy |
513,573
+40,308
| +9% | +$112K | 0.07% | 152 |
|
|
2024
Q1 | $1.72M | Sell |
473,265
-258,716
| -35% | -$939K | 0.09% | 130 |
|
|
2023
Q4 | $915K | Sell |
731,981
-32,351
| -4% | -$40.4K | 0.04% | 155 |
|
|
2023
Q3 | $764K | Sell |
764,332
-2,241
| -0.3% | -$2.24K | 0.03% | 143 |
|
|
2023
Q2 | $560K | Buy |
766,573
+293,470
| +62% | +$214K | 0.03% | 131 |
|
|
2023
Q1 | $1.29M | Hold |
473,103
| – | – | 0.07% | 132 |
|
|
2022
Q4 | $1.16M | Hold |
473,103
| – | – | 0.08% | 128 |
|
|
2022
Q3 | $1.16M | Buy |
473,103
+107,891
| +30% | +$264K | 0.1% | 135 |
|
|
2022
Q2 | $1.09M | Hold |
365,212
| – | – | 0.08% | 130 |
|
|
2022
Q1 | $1.06M | Buy |
365,212
+6,099
| +2% | +$17.7K | 0.11% | 127 |
|
|
2021
Q4 | $1.45M | Buy |
359,113
+6,694
| +2% | +$27.1K | 0.31% | 88 |
|
|
2021
Q3 | $2.21M | Buy |
352,419
+35,309
| +11% | +$221K | 0.72% | 43 |
|
|
2021
Q2 | $2.22M | Buy |
317,110
+21,009
| +7% | +$147K | 0.53% | 34 |
|
|
2021
Q1 | $1.66M | Buy |
+296,101
| New | +$1.66M | 0.37% | 46 |
|